Rhone Ma Holdings BhdXKLS:5278 61 EBITDA Margin % is 11.08% as of Mar. 2026, which is 6% below its 10-year median of 11.78. GuruFocus rates XKLS:5278 with a GF Score™ of 61/100 and a GF Value™ of RM0.80 (Modestly Undervalued). Among 956 Drug Manufacturers companies, Rhone Ma Holdings Bhd ranks worse than 51.05% on this metric.
Rhone Ma Holdings Bhd (XKLS:5278) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Rhone Ma Holdings Bhd EBITDA Margin % Related Terms
Rhone Ma Holdings Bhd EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Rhone Ma Holdings Bhd's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:5278 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhone Ma Holdings Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhone Ma Holdings Bhd EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhone Ma Holdings Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Rhone Ma Holdings Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhone Ma Holdings Bhd (XKLS:5278) has a EBITDA Margin % of 11.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rhone Ma Holdings Bhd and its competitors. This is near median its historical median of 11.78. Over the past decade, Rhone Ma Holdings Bhd's EBITDA Margin % has ranged from 10.28 to 13.74. According to the industry distribution chart, Rhone Ma Holdings Bhd ranks #488 out of 956 companies in the Drug Manufacturers industry, placing it in the top 51%.
Is Rhone Ma Holdings Bhd's EBITDA Margin % too high?
Rhone Ma Holdings Bhd's current EBITDA Margin % of 11.08% is near median its 10-year median of 11.78. Over the past 10 years, this metric has ranged from a low of 10.28 to a high of 13.74. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Rhone Ma Holdings Bhd's value of 11.08% is 11.5% below this industry median. Based on the distribution chart, Rhone Ma Holdings Bhd ranks #488 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rhone Ma Holdings Bhd has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhone Ma Holdings Bhd's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rhone Ma Holdings Bhd ranks #488 out of 956 companies for EBITDA Margin %. This places Rhone Ma Holdings Bhd in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Rhone Ma Holdings Bhd's value of 11.08% is 11.5% below this benchmark. Historically, Rhone Ma Holdings Bhd's own EBITDA Margin % has ranged from 10.28 to 13.74 over the past decade. While the company's 10-year median is 11.78 vs. the industry median of 12.52, Rhone Ma Holdings Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhone Ma Holdings Bhd's current EBITDA Margin % of 11.08% is 11.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rhone Ma Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhone Ma Holdings Bhd's current EBITDA Margin % is 11.08%, which is near median its own 10-year median of 11.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhone Ma Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd (XKLS:5278) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.80, compared to a current price of RM0.69 — trading 13.8% below its estimated fair value. The current EBITDA Margin % is 11.08%, which is near median its 10-year median of 11.78 and 11.5% below the Drug Manufacturers industry median of 12.52. Rhone Ma Holdings Bhd's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rhone Ma Holdings Bhd (XKLS:5278), the current EBITDA Margin % is 11.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhone Ma Holdings Bhd (XKLS:5278) Overvalued in 2026?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd stock appears to be undervalued.
The current stock price of RM0.69 is trading 13.8% below its estimated GF Value™ of RM0.80.
GuruFocus considers Rhone Ma Holdings Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:5278:
EBITDA Margin %: 11.08% (near median its 10-year median of 11.78)
GF Value™: RM0.80 vs. price of RM0.69 (13.8% below fair value)
Industry Position: 11.5% below the Drug Manufacturers median (#488 of 956)
No single metric tells the full story. See the XKLS:5278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhone Ma Holdings Bhd, along with its subsidiaries, is mainly involved in the provision of end-to-end animal health solutions. The Group provides veterinary consultation services, diagnostic laboratory analyses, R&D, and is engaged in the manufacturing and distribution of animal health products. Its reportable segments are: Animal health products and equipment, Food ingredients, and Others. The majority of its revenue is generated from the Animal health products and equipment segment, which is engaged in marketing, trading, distribution, and manufacturing of animal health products and equipment, such as pharmaceuticals, vaccines, feed additives, pesticides, and others. Geographically, the Group's operations are predominantly located in Malaysia.
61GF Score
Get the complete analysis for XKLS:5278
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:5278 has been successfully added to your 
